SCHEMBL16201425

SCHEMBL16201425

CCCN(C)Cc1n[nH]cc1-c1ccc(CC(C)C)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 4/20 0.35
AGTR2 P50052 4/20 0.35
CLK1 P49759 1/20 0.35
CLK2 P49760 1/20 0.35
HIPK1 Q86Z02 1/20 0.35
HIPK2 Q9H2X6 1/20 0.35
HIPK3 Q9H422 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
PRMT3 O60678 1/20 0.33
CARM1 Q86X55 1/20 0.33
PRMT6 Q96LA8 1/20 0.33
PRMT1 Q99873 1/20 0.33
PRMT8 Q9NR22 1/20 0.33
MEN1 O00255 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
XDH P47989 1/20 0.32
AKT1 P31749 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16201260 0.89 CARM1 (0.45) CLK1CLK2HIPK1HIPK2HIPK3
SCHEMBL16201371 0.85 NPSR1 (0.39) AGTR1AGTR2PRMT3CARM1PRMT6
SCHEMBL16201340 0.82 TDO2 (0.33) AGTR1AGTR2
SCHEMBL16201380 0.82 CRHR1 (0.36) AGTR1AGTR2PRMT3CARM1PRMT6
SCHEMBL16201407 0.80 KDM5A (0.34) CLK1CLK2HIPK1HIPK2HIPK3
SCHEMBL16201384 0.79 PRMT3 (0.40) AGTR1AGTR2PRMT3CARM1PRMT6
SCHEMBL16201349 0.79 HRH3 (0.43) HRH3
SCHEMBL16201358 0.79 PRMT6 (0.39) CLK1PRMT3CARM1PRMT6PRMT1
SCHEMBL16201444 0.78 LTA4H (0.41) AGTR1AGTR2MAPT
SCHEMBL16201372 0.78 SPHK1 (0.33) AGTR1AGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9346761-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2016-05-24 US disclosed
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 AGTR1 1953/4885AGTR2 2079/4885CLK1 3610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.